A changing of the guard: Dan Brennan will become Boston Scientific‘s (BSX) new CFO effective Jan. 1.
Company CFO Jeffrey Capello will stay with the company through May to help as a senior advisor and probably to help Brennan transition into the role. His reason for leaving is still vague. A company statement said he has a “desire to pursue opportunities for a broader management position.”
During Brennan’s nearly two decades with the company, he’s served as VP of finance and IT for the Cardiovascular division, VP of international finance and VP of investor relations.
Why Pharma Companies Should Look To Social Media For Better Patient Insight
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.
This comes as part of BSX’s restructuring plan. According to Seeking Alpha, that plan will “include continued implementation of BSX’s ongoing Plant Network Optimization strategy, continued focus on driving operational efficiencies and ongoing business and commercial model changes.” Plus, the company could shed as many as 1,500 jobs.
Follow MedCity News on Facebook and Twitter for more updates.